Blood pressure in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Journal of Pediatric Endocrinology and Metabolism

Volumn 19, Issue 5, 2006, Pages 705-711

  Hoepffner, Wolfgang ^a,b   Herrmann, Alexander ^a   Willgerodt, Helmut ^a   Keller, Eberhard ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

21 hydroxylase deficiency; 24 hour ambulatory blood pressure monitoring; Atrial natriuretic peptide; Blood pressure; Congenital adrenal hyperplasia (CAH)

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CORTICOSTEROID; FLUDROCORTISONE; HYDROCORTISONE; MINERALOCORTICOID; STEROID 21 MONOOXYGENASE;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BODY HEIGHT; BODY MASS; CLINICAL ARTICLE; COHORT ANALYSIS; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REGIMEN; FEMALE; HOSPITALIZATION; HUMAN; HYPERTENSION; LEISURE; MALE; OUTPATIENT; PROTEIN BLOOD LEVEL; SALT LOSING NEPHRITIS; SCHOOL CHILD; STEROID 21 MONOOXYGENASE DEFICIENCY; SYSTOLIC BLOOD PRESSURE;

EID: 33745230826     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2006.19.5.705     Document Type: Article

References (23)

1. Lopes LA, Dubuis JM, Vallotton MB, Sizonenko PC. Should we monitor more closely the dosage of 9α-fluorohydrocortisone in salt-losing congenital adrenal hyperplasia? J Pediatr Endocrinol Metab 1998; 11: 733-737.
2. Höller W, Knorr D. Hochdruck als Komplikation der AGS-Behandlung. Monatsschr Kinderheilkd 1982; 130: 734-735.
3. Vazquez AM, Kenny FM. Hypertension secondary to excessive desoxycorticosterone implants or 9-alpha fluorocortisol in salt-losing congenital adrenal hyperplasia. J Pediatr 1972; 81: 549-552.
4. Mantero F, Armanini D, Opocher G, Fallo F, Sampieri L, Cuspidi B, Ambrosi C, Faglia G. Mineralocorticoid hypertension due to a nasal spray containing 9 alpha-fluoroprednisolone. Am J Med 1981; 71: 352-357.
5. Arisaka O, Hosaka A, Arisaka M, Shimura N, Nakayama Y, Yamashiro Y, Yabuta K. Atrial natriuretic peptide and fludrocortisone therapy in congenital adrenal hyperplasia. Acta Paediatr 1992; 81: 268-269.
6. Roche EF, Charmandari E, Dattani MT, Hindmarsh P. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report. Clin Endocrinol 2003; 58: 589-596.
7. de Silva KSH, Kanumakala S, Brown JJ, Jones CL, Warne GL. 24-hour ambulatory blood pressure profile in patients with congenital adrenal hyperplasia - a preliminary report. J Pediatr Endocrinol Metab 2004; 17: 1089-1095.
8. Soergel M, Kirschstein M, Busch C, Danne T, Gellermann J, Holl R, Krull F, Reichert H, Reusz GS, Rascher W. Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: a multicenter trial including 1141 subjects. J Pediatr 1997; 130: 178-184.
9. Update on the 1987 task force report on high pressure in children and adolescents: a working group report from the National High Blood Pressure Education Program. Pediatrics 1996; 98: 649-658.
10. 1999 World Health Organisation. International Society of Hypertension guidelines for the management of hypertension. J Hypertension 1999; 17: 151-183.
11. Graettinger WF, Lipson JL, Cheung DG, Weber MA. Validation of portable noninvasive blood pressure monitoring devices: comparisons with intra-arterial and sphygmomanometer measurements. Am Heart J 1988; 116: 1155-1160.
12. Light KC, Obrist PA, Cubeddu LX. Evaluation of a new ambulatory blood pressure monitor (Accutracker 102): laboratory comparisons with direct arterial pressure, stethoscopic auscultatory pressure, and readings from a similar monitor (Spacelabs Model 5200). Psychophysiology 1988; 25: 107-116.
13. Kölling K, Kraus F, Haase HU, Redl A. Vollautomatisches Blutdruckmonitoring mit einem oszillometrisch messenden System: Genauigkeit und Akteptanz. Nieren- und Hochdruckkrankh 1992; 21: 448-452.
14. Bald M, Kubel S, Rascher W. Validity and reliability of 24h blood pressure monitoring in children and adolescents using a portable, oscillometric device. J Hum Hypertens 1994; 8: 363-366.
15. Portman RJ, Yetman RJ, West MS. Efficacy of 24-hour ambulatory blood pressure monitoring in children. J Pediatr 1991; 118: 842-849.
16. Khan IA, Gajaria M, Stephens D, Balfe JW. Ambulatory blood pressure monitoring in children: a large center's experience. Pediatr Nephrol 2000; 14: 802-805.
17. Egger M, Bianchetti MG, Gnadinger M, Kobelt R, Oetliker O. Twenty four hour intermittent, ambulatory blood pressure monitoring. Arch Dis Child 1987; 62: 1130-1135.
18. Reichert H, Hoffmann W. Experiences with ambulatory long-term blood pressure measurement in childhood and adolescence. Klin Paediatr 1990; 202: 408-412.
19. Daniels SR, Loggie JM, Burton T, Kaplan S. Difficulties with ambulatory blood pressure monitoring in children and adolescents. J Pediatr 1987; 111: 397-400.
20. Cutler GB Jr, Laue L. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1990; 323: 1806-1813.
21. Brook CG. The management of classical congenital adrenal hyperplasia due to 21 -hydroxylase deficiency. Clin Endocrinol (Oxf) 1990; 33: 559-567.
22. Reinken L, van Oost G. Longitudinale Körperentwicklung gesunder Kinder von 0-18 Jahren. Klin Pädiatr 1992; 204: 129-133.
23. Kromeyer-Hauschild K, Wabitsch M, Kunze D, et al. Perzentile für den Body-mass-Index für das Kindes-und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschr Kinderheilk 2001; 149: 807-818.